Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 2Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2

Interventions

Specimen Handling 49pembrolizumab 44Magnetic Resonance Spectroscopy 37Biopsy 35Cyclophosphamide 33fludarabine 28Cetuximab 20Cisplatin 19Carboplatin 19Bevacizumab 16atezolizumab 15Radiation 15venetoclax 14Fluorouracil 14fludarabine phosphate 13Radiotherapy 13Leucovorin 13Nivolumab 12Gemcitabine 12Pemetrexed 11Oxaliplatin 11Cytarabine 11Irinotecan 10130-nm albumin-bound paclitaxel 10Prednisone 9Paclitaxel 9Immunoglobulin G 9Fulvestrant 9durvalumab 8Temozolomide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Gemtuzumab × 30 days × Clear all
NCT04915612 2026-05-20

Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1 Completed
1 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03900949 2026-05-15

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
21 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡